About this Research Topic
Cognitive and emotional behavioral derangements are the most common comorbidities of epileptic disorders in children. The clinical approach to these comorbidities is challenging due to their heterogeneous etiologies that include among others, underlying brain pathologies, early life seizures, status epilepticus, genetic factors and anti-seizure medications. Dissecting these various contributing factors in the clinical and preclinical arenas along with an increased insight into their genetic, cellular, and molecular underpinnings is key to devise the best treatment strategies, and may provide molecular targets for novel therapies.
Neurodevelopmental cognitive and emotional deficits are the most common comorbidities of the epilepsies and their effects on quality of life may be as drastic as seizure themselves. Understanding their causative factors will help in attenuating or even preventing these comorbidities. We will seek research work that identifies the role of potentially reversible contributing factors and their treatment. This category includes mostly clinical research papers on the negative developmental effects of early life seizures, status epilepticus (SE), electrical SE during sleep (ESES), and the notorious adverse effects of anti-seizure medications. This research topic will also be enriched by the growing data on the neurogenetic conditions that cause epilepsy and behavioral deficits, including some of the booming literature on epilepsy and autistic features. From a preclinical angle, converging lines of evidence point to the long-term detrimental effects of early life seizures, specifically status epilepticus, on cognitive and emotional neurodevelopment in animal models. Identifying the underlying molecular underpinnings in this line of research may provide targets for future novel therapies.
Topic Editors will welcome research articles of all types about, but not limited to:
· Cognitive and psychiatric comorbidities in pediatric epilepsies, prevalence, types, natural history, and treatment response (clinical original, one review)
· Cognitive and psychiatric comorbidities of anti-seizure medications (original, mainly clinical, one review)
· The potential cognitive and emotional developmental deficits following brain lesions, SE, ESES, and early life seizures including neonatal seizures (clinical original, one review)
· Later life cognitive and emotional developmental deficits following early life seizures and SE in immature animal seizure models (original preclinical on behavioral studies, molecular, genetic, electrophysiology, and novel treatment strategies, one review)
· Neurogenetic syndromes with overlapping behavioral deficits and epilepsy (original clinical descriptive and mechanistic, one review)
Keywords: Epilepsy, genetic, molecular, anti-seizure medications, neurodevelopment, Pediatric, clinical research, preclinical research
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.